首页 > 最新文献

Blood Pressure最新文献

英文 中文
A systematic review of commencing full-dose antihypertensives in newly diagnosed hypertension. 新诊断高血压开始全剂量抗高血压药物的系统回顾。
IF 2.3 4区 医学 Pub Date : 2025-12-01 Epub Date: 2025-12-11 DOI: 10.1080/08037051.2025.2594268
Babu Karavadra, Alexander D Elia, Alena Shantsila, Gregory Y H Lip, Eduard Shantsila

Background: Hypertension is the UK's most common treatable cause of mortality and morbidity, including cardiovascular disease (CVD), renal disease and dementia.

Objective: This systematic review has explored the efficacy and safety of commencing full-dose antihypertensive treatment in individuals with essential hypertension.

Method: Method16 randomised controlled trials (RCTs) were eligible for inclusion, with some RCTs assessing more than one treatment. The review assessed commonly used antihypertensive drugs (perindopril 8 mg, ramipril 10 mg, amlodipine 10 mg, losartan 100 mg, irbesartan 300 mg, candesartan 16 mg and candesartan 32 mg) compared to low starting doses or placebo RCTs. Eligible studies included 12 RCTs that compared full vs low doses and 19 RCTs that compared full starting doses vs placebo. The primary outcome was the difference in blood pressure reduction compared to controls (reported or calculated). ResultsUsing full doses compared to low doses led to better BP reduction (overall, 3.9/2.2 mmHg lower achieved BP) without an increase in adverse effects. This notion is supported by the changes achieved with full-dose treatment initiation compared to placebo (average over all studies: 11.4 [4.4]/6.5 [2.9] mmHg).

Conclusions: This review indicates that initiating full-dose antihypertensives for essential hypertension may be beneficial and safe. The available data are limited, and further RCTs are required to assess this in specific patient groups to assess safety and efficac.

本系统综述探讨了原发性高血压患者开始全剂量降压治疗的有效性和安全性。16项随机对照试验(RCT)符合纳入条件,其中一些RCT评估了不止一种治疗。该综述评估了常用的降压药(培哚普利8毫克,雷米普利10毫克,氨氯地平10毫克,氯沙坦100毫克,厄贝沙坦300毫克,坎地沙坦16毫克,坎地沙坦32毫克)与低起始剂量或安慰剂随机对照试验的比较。符合条件的研究包括12项比较全剂量与低剂量的随机对照试验,19项比较全起始剂量与安慰剂的随机对照试验。主要结局是与对照组相比血压降低的差异(报告或计算)。与低剂量相比,使用全剂量可以更好地降低血压(总体而言,降低3.9/2.2 mmHg达到血压),而不会增加不良反应。与安慰剂相比,全剂量治疗开始时取得的变化支持了这一观点(所有研究的平均值:11.4 [4.4]/6.5 [2.9]mmHg)。综述表明,开始全剂量抗高血压药物治疗原发性高血压可能是有益和安全的。现有数据有限,需要进一步的随机对照试验对特定患者群体进行评估,以评估安全性和有效性。
{"title":"A systematic review of commencing full-dose antihypertensives in newly diagnosed hypertension.","authors":"Babu Karavadra, Alexander D Elia, Alena Shantsila, Gregory Y H Lip, Eduard Shantsila","doi":"10.1080/08037051.2025.2594268","DOIUrl":"10.1080/08037051.2025.2594268","url":null,"abstract":"<p><strong>Background: </strong>Hypertension is the UK's most common treatable cause of mortality and morbidity, including cardiovascular disease (CVD), renal disease and dementia.</p><p><strong>Objective: </strong>This systematic review has explored the efficacy and safety of commencing full-dose antihypertensive treatment in individuals with essential hypertension.</p><p><strong>Method: </strong>Method16 randomised controlled trials (RCTs) were eligible for inclusion, with some RCTs assessing more than one treatment. The review assessed commonly used antihypertensive drugs (perindopril 8 mg, ramipril 10 mg, amlodipine 10 mg, losartan 100 mg, irbesartan 300 mg, candesartan 16 mg and candesartan 32 mg) compared to low starting doses or placebo RCTs. Eligible studies included 12 RCTs that compared full vs low doses and 19 RCTs that compared full starting doses vs placebo. The primary outcome was the difference in blood pressure reduction compared to controls (reported or calculated). ResultsUsing full doses compared to low doses led to better BP reduction (overall, 3.9/2.2 mmHg lower achieved BP) without an increase in adverse effects. This notion is supported by the changes achieved with full-dose treatment initiation compared to placebo (average over all studies: 11.4 [4.4]/6.5 [2.9] mmHg).</p><p><strong>Conclusions: </strong>This review indicates that initiating full-dose antihypertensives for essential hypertension may be beneficial and safe. The available data are limited, and further RCTs are required to assess this in specific patient groups to assess safety and efficac.</p>","PeriodicalId":9000,"journal":{"name":"Blood Pressure","volume":" ","pages":"2594268"},"PeriodicalIF":2.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145687002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Intradialytic Hypotension Pathophysiology and Therapy Update: Review and Update. 分析性低血压的病理生理学和治疗更新:回顾和更新。
IF 1.8 4区 医学 Pub Date : 2025-02-27 DOI: 10.1080/08037051.2025.2469260
Elmukhtar Habas, Amnna Rayani, Aml Habas, Kalifa Farfar, Eshrak Habas, Khaled Alarbi, Ala Habas, Elmehdi Errayes, Gamal Alfitori

BackgroundIntradialytic hypotension (IDH) is the most prevalent complication during hemodialysis (HD) sessions, affecting 10% to 12% of patients. It is linked with temporary ischemic stress in vital organs, increasing patient mortality. Various definitions of IDH have been proposed, and a strong correlation has been found between patient outcomes and the absolute lowest systolic blood pressure. The most probable underlying pathophysiology of IDH involves a reduced effective blood volume and decreased plasma tonicity. Optimizing the dialysis prescription and interventions during and after the dialysis session is sometimes effective for reducing IDH risk.Aim and MethodThis review discusses the pathophysiology, prevention, and therapy of IDH updates. To achieve this aim, Scopus, EMBASE, PubMed, Google, and Google Scholar were searched for articles published in the last two decades using phrases and keywords.ConclusionIntradialytic pathophysiology is ambiguous and unclear. The evidence for the effectiveness of the known therapies and maneuvers is limited. Ideally, IDH prevention should be the target; however, IDH management is sometimes needed. Different obstacles require further clinical research.

传统分析性低血压(IDH)是血液透析(HD)期间最常见的并发症,影响10%至12%的患者。它与重要器官的暂时性缺血应激有关,增加了病人的死亡率。IDH的各种定义已经提出,并且发现患者预后与绝对最低收缩压之间存在很强的相关性。IDH最可能的潜在病理生理机制包括有效血容量减少和血浆强直性降低。在透析期间和之后优化透析处方和干预措施有时对降低IDH风险有效。目的与方法综述IDH更新的病理生理、预防和治疗。为了实现这一目标,我们使用短语和关键字对Scopus、EMBASE、PubMed、谷歌和谷歌Scholar检索了近二十年来发表的文章。结论分析内病理生理不明确。已知的治疗方法和操作的有效性的证据是有限的。理想情况下,预防IDH应该是目标;然而,有时需要IDH管理。不同的障碍需要进一步的临床研究。
{"title":"Intradialytic Hypotension Pathophysiology and Therapy Update: Review and Update.","authors":"Elmukhtar Habas, Amnna Rayani, Aml Habas, Kalifa Farfar, Eshrak Habas, Khaled Alarbi, Ala Habas, Elmehdi Errayes, Gamal Alfitori","doi":"10.1080/08037051.2025.2469260","DOIUrl":"https://doi.org/10.1080/08037051.2025.2469260","url":null,"abstract":"<p><p>BackgroundIntradialytic hypotension (IDH) is the most prevalent complication during hemodialysis (HD) sessions, affecting 10% to 12% of patients. It is linked with temporary ischemic stress in vital organs, increasing patient mortality. Various definitions of IDH have been proposed, and a strong correlation has been found between patient outcomes and the absolute lowest systolic blood pressure. The most probable underlying pathophysiology of IDH involves a reduced effective blood volume and decreased plasma tonicity. Optimizing the dialysis prescription and interventions during and after the dialysis session is sometimes effective for reducing IDH risk.Aim and MethodThis review discusses the pathophysiology, prevention, and therapy of IDH updates. To achieve this aim, Scopus, EMBASE, PubMed, Google, and Google Scholar were searched for articles published in the last two decades using phrases and keywords.ConclusionIntradialytic pathophysiology is ambiguous and unclear. The evidence for the effectiveness of the known therapies and maneuvers is limited. Ideally, IDH prevention should be the target; however, IDH management is sometimes needed. Different obstacles require further clinical research.</p>","PeriodicalId":9000,"journal":{"name":"Blood Pressure","volume":" ","pages":"1-18"},"PeriodicalIF":1.8,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143514418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Letter to the editor. 致编辑的信
IF 1.8 4区 医学 Pub Date : 2024-12-01 Epub Date: 2024-08-06 DOI: 10.1080/08037051.2024.2385159
Jorge Polónia, Raul Marques Pereira
{"title":"Letter to the editor.","authors":"Jorge Polónia, Raul Marques Pereira","doi":"10.1080/08037051.2024.2385159","DOIUrl":"10.1080/08037051.2024.2385159","url":null,"abstract":"","PeriodicalId":9000,"journal":{"name":"Blood Pressure","volume":"33 1","pages":"2385159"},"PeriodicalIF":1.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141892745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hypertension and its correlation with autonomic nervous system dysfunction, heart rate variability and chronic inflammation. 高血压及其与自律神经系统功能障碍、心率变异性和慢性炎症的相关性。
IF 1.8 4区 医学 Pub Date : 2024-12-01 Epub Date: 2024-09-23 DOI: 10.1080/08037051.2024.2405156
Bo He, Dapeng Ji, Bo Zhang

Objective: This study investigates the relationship between hypertension, dysregulation of the autonomic nervous system, heart rate variability (HRV), and chronic inflammation.

Methods: We analysed a cohort of 50 hypertensive patients treated at the affiliated Hospital of Jianghan University. The average systolic and diastolic blood pressures (BPs) in this group were 155.26 and 95.32 mmHg, respectively. A control group of 50 healthy volunteers, undergoing routine physical examinations at the same hospital, was also analysed.

Results: The average systolic BP of the control group was 115.64 ± 10.27 mmHg, and the average diastolic BP was 75.33 ± 8.25 mmHg. In contrast, the experimental group exhibited an average systolic BP of 155.26 ± 20.13 mmHg and an average diastolic BP of 95.32 ± 12.16 mmHg. Both systolic and diastolic BPs were significantly higher in the hypertensive group (p < 0.05). The experimental group also demonstrated reduced HRV and skin conductance response, alongside increased BP variability (BPV), urinary epinephrine levels and prolonged pupillary light reaction time compared to controls (p < 0.05). Notably, Standard Deviation of Normal to Normal Intervals (SDNN) and Root Mean Square of Successive Differences (RMSSD) values were significantly lower in the experimental group (p < 0.05). Furthermore, levels of inflammatory markers such as CRP, TNF-α, IL-6 and IL-1β were markedly elevated in hypertensive patients (p < 0.05). Negative correlations were observed between systolic and diastolic BP with HRV metrics, while positive correlations were found between BP and BPV as well as urinary adrenaline levels.

Conclusions: The findings indicate that hypertension is closely associated with autonomic nervous system dysfunction, reduced HRV and increased chronic inflammation. A comprehensive approach to hypertension management should integrate these interrelated physiological and pathological mechanisms, with potential therapeutic interventions targeting autonomic function and inflammatory states.

目的:本研究探讨了高血压、自律神经系统失调、心率变异性和慢性炎症之间的关系:本研究探讨了高血压、自主神经系统失调、心率变异性(HRV)和慢性炎症之间的关系:我们分析了在江汉大学附属医院接受治疗的 50 名高血压患者。该组患者的平均收缩压和舒张压分别为 155.26 毫米汞柱和 95.32 毫米汞柱。同时还分析了在同一家医院接受常规体检的 50 名健康志愿者组成的对照组:结果:对照组的平均收缩压为 115.64 ± 10.27 mmHg,平均舒张压为 75.33 ± 8.25 mmHg。相比之下,实验组的平均收缩压为(155.26 ± 20.13)毫米汞柱,平均舒张压为(95.32 ± 12.16)毫米汞柱。高血压组的收缩压和舒张压均明显高于实验组(P P P P 结论):研究结果表明,高血压与自律神经系统功能障碍、心率变异性降低和慢性炎症增加密切相关。治疗高血压的综合方法应整合这些相互关联的生理和病理机制,并针对自律神经功能和炎症状态采取潜在的治疗干预措施。
{"title":"Hypertension and its correlation with autonomic nervous system dysfunction, heart rate variability and chronic inflammation.","authors":"Bo He, Dapeng Ji, Bo Zhang","doi":"10.1080/08037051.2024.2405156","DOIUrl":"https://doi.org/10.1080/08037051.2024.2405156","url":null,"abstract":"<p><strong>Objective: </strong>This study investigates the relationship between hypertension, dysregulation of the autonomic nervous system, heart rate variability (HRV), and chronic inflammation.</p><p><strong>Methods: </strong>We analysed a cohort of 50 hypertensive patients treated at the affiliated Hospital of Jianghan University. The average systolic and diastolic blood pressures (BPs) in this group were 155.26 and 95.32 mmHg, respectively. A control group of 50 healthy volunteers, undergoing routine physical examinations at the same hospital, was also analysed.</p><p><strong>Results: </strong>The average systolic BP of the control group was 115.64 ± 10.27 mmHg, and the average diastolic BP was 75.33 ± 8.25 mmHg. In contrast, the experimental group exhibited an average systolic BP of 155.26 ± 20.13 mmHg and an average diastolic BP of 95.32 ± 12.16 mmHg. Both systolic and diastolic BPs were significantly higher in the hypertensive group (<i>p</i> < 0.05). The experimental group also demonstrated reduced HRV and skin conductance response, alongside increased BP variability (BPV), urinary epinephrine levels and prolonged pupillary light reaction time compared to controls (<i>p</i> < 0.05). Notably, Standard Deviation of Normal to Normal Intervals (SDNN) and Root Mean Square of Successive Differences (RMSSD) values were significantly lower in the experimental group (<i>p</i> < 0.05). Furthermore, levels of inflammatory markers such as CRP, TNF-α, IL-6 and IL-1β were markedly elevated in hypertensive patients (<i>p</i> < 0.05). Negative correlations were observed between systolic and diastolic BP with HRV metrics, while positive correlations were found between BP and BPV as well as urinary adrenaline levels.</p><p><strong>Conclusions: </strong>The findings indicate that hypertension is closely associated with autonomic nervous system dysfunction, reduced HRV and increased chronic inflammation. A comprehensive approach to hypertension management should integrate these interrelated physiological and pathological mechanisms, with potential therapeutic interventions targeting autonomic function and inflammatory states.</p>","PeriodicalId":9000,"journal":{"name":"Blood Pressure","volume":"33 1","pages":"2405156"},"PeriodicalIF":1.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142280147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A sham-controlled randomised pilot trial on baroreflex activation therapy in patients with resistant hypertension: What will the future hold? 针对耐药性高血压的气压反射激活疗法的假对照随机试验。
IF 1.8 4区 医学 Pub Date : 2024-12-01 Epub Date: 2024-10-23 DOI: 10.1080/08037051.2024.2417887
D Gordin, R Simonsen, I Tikkanen
{"title":"A sham-controlled randomised pilot trial on baroreflex activation therapy in patients with resistant hypertension: What will the future hold?","authors":"D Gordin, R Simonsen, I Tikkanen","doi":"10.1080/08037051.2024.2417887","DOIUrl":"10.1080/08037051.2024.2417887","url":null,"abstract":"","PeriodicalId":9000,"journal":{"name":"Blood Pressure","volume":"33 1","pages":"2417887"},"PeriodicalIF":1.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142494646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association of childhood socioeconomic status with adulthood maximal exercise blood pressure: the Cardiovascular Risk in Young Finns Study. 童年社会经济地位与成年后最大运动血压的关系:芬兰年轻人心血管风险研究。
IF 1.8 4区 医学 Pub Date : 2024-12-01 Epub Date: 2024-03-11 DOI: 10.1080/08037051.2024.2323987
Erika Kähönen, Emilia Kähönen, Kristiina Pälve, Janne Hulkkonen, Mika Kähönen, Olli T Raitakari, Nina Hutri, Terho Lehtimäki, Heikki Aatola

Purpose: Socioeconomic status has been related to resting blood pressure (BP) levels at different stages of life. However, the association of childhood socioeconomic status (SES) and adulthood exercise BP is largely unknown. Therefore, we studied the association of childhood SES with adulthood maximal exercise BP.

Materials and methods: This investigation consisted of 373 individuals (53% women) participating in the Cardiovascular Risk in Young Finns Study who had data concerning family SES in childhood (baseline in 1980, at age of 6-18 years) and exercise BP response data in adulthood (follow-up in adulthood in 27-29 years since baseline). A maximal cardiopulmonary exercise test with BP measurements was performed by participants, and peak exercise BP was measured.

Results: In stepwise multivariable analysis including childhood risk factors and lifestyle factors (body mass index, systolic BP, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, insulin, fruit consumption, vegetable consumption, and physical activity), lower family SES in childhood was associated with higher maximal exercise BP in adulthood (β value ± SE, 1.63 ± 0.77, p = 0.035). The association remained significant after further adjustment with participants SES in adulthood (β value ± SE, 1.68 ± 0.65, p = 0.011) and after further adjustment with adulthood body-mass index, systolic BP, maximal exercise capacity, and peak heart rate in exercise (β value ± SE, 1.25 ± 0.56, p = 0.027).

Conclusions: These findings suggest that lower childhood family SES is associated with higher maximal exercise BP in adulthood.

目的:社会经济地位与人生不同阶段的静息血压(BP)水平有关。然而,儿童时期的社会经济地位(SES)与成年后运动血压之间的关系在很大程度上还不为人所知。因此,我们研究了儿童期社会经济地位与成年期最大运动血压的关系:这项调查由 373 名参与芬兰年轻人心血管风险研究的人员(53% 为女性)组成,他们拥有童年时期(1980 年,6-18 岁时的基线)的家庭 SES 数据和成年后(自基线起 27-29 年的成年后随访)的运动血压反应数据。参与者进行了最大心肺运动测试和血压测量,并测量了运动血压峰值:在包括儿童期风险因素和生活方式因素(体重指数、收缩压、低密度脂蛋白胆固醇、高密度脂蛋白胆固醇、甘油三酯、胰岛素、水果摄入量、蔬菜摄入量和体育锻炼)的逐步多变量分析中,儿童期较低的家庭社会经济地位与成年期较高的最大运动血压相关(β值±SE,1.63±0.77,p = 0.035)。在进一步调整参与者成年时的社会经济地位(β值±SE,1.68±0.65,p = 0.011)以及成年时的体重指数、收缩压、最大运动能力和运动时的峰值心率(β值±SE,1.25±0.56,p = 0.027)后,这种关联仍然显著:这些研究结果表明,儿童时期较低的家庭社会经济地位与成年后较高的最大运动血压有关。
{"title":"Association of childhood socioeconomic status with adulthood maximal exercise blood pressure: the Cardiovascular Risk in Young Finns Study.","authors":"Erika Kähönen, Emilia Kähönen, Kristiina Pälve, Janne Hulkkonen, Mika Kähönen, Olli T Raitakari, Nina Hutri, Terho Lehtimäki, Heikki Aatola","doi":"10.1080/08037051.2024.2323987","DOIUrl":"10.1080/08037051.2024.2323987","url":null,"abstract":"<p><strong>Purpose: </strong>Socioeconomic status has been related to resting blood pressure (BP) levels at different stages of life. However, the association of childhood socioeconomic status (SES) and adulthood exercise BP is largely unknown. Therefore, we studied the association of childhood SES with adulthood maximal exercise BP.</p><p><strong>Materials and methods: </strong>This investigation consisted of 373 individuals (53% women) participating in the Cardiovascular Risk in Young Finns Study who had data concerning family SES in childhood (baseline in 1980, at age of 6-18 years) and exercise BP response data in adulthood (follow-up in adulthood in 27-29 years since baseline). A maximal cardiopulmonary exercise test with BP measurements was performed by participants, and peak exercise BP was measured.</p><p><strong>Results: </strong>In stepwise multivariable analysis including childhood risk factors and lifestyle factors (body mass index, systolic BP, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, insulin, fruit consumption, vegetable consumption, and physical activity), lower family SES in childhood was associated with higher maximal exercise BP in adulthood (β value ± SE, 1.63 ± 0.77, <i>p</i> = 0.035). The association remained significant after further adjustment with participants SES in adulthood (β value ± SE, 1.68 ± 0.65, <i>p</i> = 0.011) and after further adjustment with adulthood body-mass index, systolic BP, maximal exercise capacity, and peak heart rate in exercise (β value ± SE, 1.25 ± 0.56, <i>p</i> = 0.027).</p><p><strong>Conclusions: </strong>These findings suggest that lower childhood family SES is associated with higher maximal exercise BP in adulthood.</p>","PeriodicalId":9000,"journal":{"name":"Blood Pressure","volume":"33 1","pages":"2323987"},"PeriodicalIF":1.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140093430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Long-term trajectory of renal dysfunction and related risk factors in patients with apparently treatment-resistant and non-resistant arterial hypertension. 明显耐药和非耐药动脉高血压患者肾功能障碍的长期轨迹及相关风险因素。
IF 1.8 4区 医学 Pub Date : 2024-12-01 Epub Date: 2024-06-07 DOI: 10.1080/08037051.2024.2353836
Zdeněk Ramík, Jan Václavík, Tomáš Kvapil, Libor Jelínek, Eva Kociánová, Monika Kamasová, Klára Benešová, Jiří Jarkovský, Martin Drápela, Zdeněk Lys

Objectives: Evidence suggests that renal function increasingly deteriorates in patients with apparently treatment-resistant hypertension (ATRH) in comparison with those who have non-resistant arterial hypertension (NAH). We aimed to assess the long-term decline in renal function between these patient groups and identify specific risk factors contributing to the progression of renal dysfunction. Methods: Data for 265 patients with ATRH and NAH in a hypertension excellence centre were retrospectively evaluated. Demographic characteristics, co-morbidities, laboratory findings, secondary causes of hypertension, medication and exposure to contrast agents were assessed. To address differences between groups, adjustment with linear mixed-effect models was used. Results: Data from the first 4 years of follow-up were evaluated. After adjustment for age and diabetes, which were identified as independent risk factors for renal dysfunction progression in the study cohort, the mean decrease in estimated glomerular filtration rate per year was steeper with ATRH than with NAH (-1.49 vs. -0.65 mL/min/1.73 m2 per year; difference in slope, 0.83 mL/min/1.73 m2 per year; 95% confidence interval [CI]: 0.25-1.41, p = 0.005). In subgroup analyses, without Holm-Bonferroni correction, the prescription of MRA indicated a faster decline in renal function in ATRH. Following correction, no specific therapeutic risk factor was associated with faster progression of renal dysfunction. Conclusions: Renal function declines twice as fast with ATRH compared with NAH, independently of age and diabetes. Larger studies are needed to reveal risk factors for renal dysfunction in patients with hypertension.

目的:有证据表明,与非耐药性动脉高血压(NAH)患者相比,明显耐药性高血压(ATRH)患者的肾功能会日益恶化。我们旨在评估这些患者群体之间肾功能的长期衰退情况,并确定导致肾功能障碍恶化的特定风险因素。研究方法我们对一家高血压卓越中心的 265 名 ATRH 和 NAH 患者的数据进行了回顾性评估。评估了人口统计学特征、合并疾病、实验室检查结果、继发性高血压病因、药物治疗和造影剂暴露情况。针对组间差异,采用线性混合效应模型进行调整。研究结果对前 4 年的随访数据进行了评估。年龄和糖尿病被确定为研究队列中肾功能不全恶化的独立风险因素,在对年龄和糖尿病进行调整后,ATRH 患者的估计肾小球滤过率每年平均下降的幅度比 NAH 患者更大(-1.49 对 -0.65 mL/min/1.73 m2/年;斜率差异为 0.83 mL/min/1.73 m2/年;95% 置信区间 [CI]:0.25-1.41,P<0.05):0.25-1.41, p = 0.005).在未进行 Holm-Bonferroni 校正的亚组分析中,处方 MRA 表明 ATRH 患者的肾功能下降更快。经过校正后,没有任何特定的治疗风险因素与肾功能障碍的加速进展相关。结论与 NAH 相比,ATRH 的肾功能下降速度是 NAH 的两倍,与年龄和糖尿病无关。需要进行更大规模的研究,以揭示高血压患者肾功能障碍的风险因素。
{"title":"Long-term trajectory of renal dysfunction and related risk factors in patients with apparently treatment-resistant and non-resistant arterial hypertension.","authors":"Zdeněk Ramík, Jan Václavík, Tomáš Kvapil, Libor Jelínek, Eva Kociánová, Monika Kamasová, Klára Benešová, Jiří Jarkovský, Martin Drápela, Zdeněk Lys","doi":"10.1080/08037051.2024.2353836","DOIUrl":"https://doi.org/10.1080/08037051.2024.2353836","url":null,"abstract":"<p><p><b>Objectives:</b> Evidence suggests that renal function increasingly deteriorates in patients with apparently treatment-resistant hypertension (ATRH) in comparison with those who have non-resistant arterial hypertension (NAH). We aimed to assess the long-term decline in renal function between these patient groups and identify specific risk factors contributing to the progression of renal dysfunction. <b>Methods:</b> Data for 265 patients with ATRH and NAH in a hypertension excellence centre were retrospectively evaluated. Demographic characteristics, co-morbidities, laboratory findings, secondary causes of hypertension, medication and exposure to contrast agents were assessed. To address differences between groups, adjustment with linear mixed-effect models was used. <b>Results:</b> Data from the first 4 years of follow-up were evaluated. After adjustment for age and diabetes, which were identified as independent risk factors for renal dysfunction progression in the study cohort, the mean decrease in estimated glomerular filtration rate per year was steeper with ATRH than with NAH (-1.49 <i>vs.</i> -0.65 mL/min/1.73 m<sup>2</sup> per year; difference in slope, 0.83 mL/min/1.73 m<sup>2</sup> per year; 95% confidence interval [CI]: 0.25-1.41, <i>p</i> = 0.005). In subgroup analyses, without Holm-Bonferroni correction, the prescription of MRA indicated a faster decline in renal function in ATRH. Following correction, no specific therapeutic risk factor was associated with faster progression of renal dysfunction. <b>Conclusions:</b> Renal function declines twice as fast with ATRH compared with NAH, independently of age and diabetes. Larger studies are needed to reveal risk factors for renal dysfunction in patients with hypertension.</p>","PeriodicalId":9000,"journal":{"name":"Blood Pressure","volume":"33 1","pages":"2353836"},"PeriodicalIF":1.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141282960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Implications of pulse wave velocity and central pulse pressure in heart failure with reduced ejection fraction. 脉搏波速度和中心脉压对射血分数降低型心力衰竭的影响。
IF 1.8 4区 医学 Pub Date : 2024-12-01 Epub Date: 2024-05-31 DOI: 10.1080/08037051.2024.2359932
Anette Caroline Kõre, Tuuli Joonsalu, Martin Serg, Priit Pauklin, Jüri Voitk, Indrek Roose, Jaan Eha, Priit Kampus

Background: Carotid-femoral pulse wave velocity (cfPWV) and central pulse pressure (PP) are recognised as significant indicators of vascular health and predictors of cardiovascular outcomes. In this study, associations between central hemodynamics and left ventricular (LV) echocardiographic parameters were investigated in subjects with heart failure with reduced ejection fraction (HFrEF), comparing the results to healthy individuals.

Methods and results: This cross-sectional prospective controlled study included 50 subjects with HFrEF [mean LV ejection fraction (EF) 26 ± 6.5%] and 30 healthy controls (mean LVEF 65.9 ± 5.3%). Pulse wave analysis (PWA) and carotid-femoral pulse wave velocity (cfPWV) were used to measure central hemodynamics and arterial stiffness. The HFrEF group displayed higher cfPWV (8.2 vs. 7.2 m/s, p = 0.007) and lower central (111.3 vs. 121.7 mmHg, p = 0.001) and peripheral (120.1 vs. 131.5 mmHg, p = 0.002) systolic blood pressure. Central pulse pressure (PP) was comparable between the two groups (37.6 vs. 40.4 mmHg, p = 0.169). In the HFrEF group, cfPWV significantly correlated with left ventricular end-diastolic volume (LVEDV) index (mL/m2) and LVEF, with LVEDV index being a significant independent predictor of cfPWV (R2 = 0.42, p = 0.003). Central PP was significantly associated with heart rate, LVEF and LVEDV index, with the latter being a significant independent predictor of central PP (R2 = 0.41, p < 0.001). These correlations were not observed in healthy controls.

Conclusions: Significant associations between central hemodynamic measures and LV echocardiographic parameters were identified, suggesting the potential to use PWA and cfPWV as possible tools for managing HFrEF.

背景:颈动脉-股动脉脉搏波速度(cfPWV)和中心脉压(PP)被认为是血管健康的重要指标和心血管预后的预测因子。本研究调查了射血分数降低型心力衰竭(HFrEF)患者的中心血流动力学与左心室(LV)超声心动图参数之间的关系,并将结果与健康人进行了比较:这项横断面前瞻性对照研究包括 50 名射血分数降低型心力衰竭患者(平均左心室射血分数(EF)26 ± 6.5%)和 30 名健康对照者(平均左心室射血分数(LVEF)65.9 ± 5.3%)。脉搏波分析(PWA)和颈动脉-股动脉脉搏波速度(cfPWV)用于测量中心血流动力学和动脉僵化。HFrEF 组的 cfPWV 较高(8.2 对 7.2 m/s,p = 0.007),中心收缩压(111.3 对 121.7 mmHg,p = 0.001)和外周收缩压(120.1 对 131.5 mmHg,p = 0.002)较低。两组的中心脉压(PP)相当(37.6 vs. 40.4 mmHg,p = 0.169)。在 HFrEF 组,cfPWV 与左心室舒张末期容积(LVEDV)指数(mL/m2)和 LVEF 显著相关,其中 LVEDV 指数是 cfPWV 的重要独立预测因子(R2 = 0.42,p = 0.003)。中心 PP 与心率、LVEF 和 LVEDV 指数有明显相关性,后者是中心 PP 的重要独立预测因子(R2 = 0.41,p 结论:中心 PP 与心率、LVEF 和 LVEDV 指数有明显相关性,后者是中心 PP 的重要独立预测因子:中心血流动力学指标与左心室超声心动图参数之间存在明显关联,这表明有可能使用 PWA 和 cfPWV 作为管理 HFrEF 的工具。
{"title":"Implications of pulse wave velocity and central pulse pressure in heart failure with reduced ejection fraction.","authors":"Anette Caroline Kõre, Tuuli Joonsalu, Martin Serg, Priit Pauklin, Jüri Voitk, Indrek Roose, Jaan Eha, Priit Kampus","doi":"10.1080/08037051.2024.2359932","DOIUrl":"https://doi.org/10.1080/08037051.2024.2359932","url":null,"abstract":"<p><strong>Background: </strong>Carotid-femoral pulse wave velocity (cfPWV) and central pulse pressure (PP) are recognised as significant indicators of vascular health and predictors of cardiovascular outcomes. In this study, associations between central hemodynamics and left ventricular (LV) echocardiographic parameters were investigated in subjects with heart failure with reduced ejection fraction (HFrEF), comparing the results to healthy individuals.</p><p><strong>Methods and results: </strong>This cross-sectional prospective controlled study included 50 subjects with HFrEF [mean LV ejection fraction (EF) 26 ± 6.5%] and 30 healthy controls (mean LVEF 65.9 ± 5.3%). Pulse wave analysis (PWA) and carotid-femoral pulse wave velocity (cfPWV) were used to measure central hemodynamics and arterial stiffness. The HFrEF group displayed higher cfPWV (8.2 vs. 7.2 m/s, <i>p</i> = 0.007) and lower central (111.3 vs. 121.7 mmHg, <i>p</i> = 0.001) and peripheral (120.1 vs. 131.5 mmHg, <i>p</i> = 0.002) systolic blood pressure. Central pulse pressure (PP) was comparable between the two groups (37.6 vs. 40.4 mmHg, <i>p</i> = 0.169). In the HFrEF group, cfPWV significantly correlated with left ventricular end-diastolic volume (LVEDV) index (mL/m<sup>2</sup>) and LVEF, with LVEDV index being a significant independent predictor of cfPWV (R<sup>2</sup> = 0.42, <i>p</i> = 0.003). Central PP was significantly associated with heart rate, LVEF and LVEDV index, with the latter being a significant independent predictor of central PP (R<sup>2</sup> = 0.41, <i>p</i> < 0.001). These correlations were not observed in healthy controls.</p><p><strong>Conclusions: </strong>Significant associations between central hemodynamic measures and LV echocardiographic parameters were identified, suggesting the potential to use PWA and cfPWV as possible tools for managing HFrEF.</p>","PeriodicalId":9000,"journal":{"name":"Blood Pressure","volume":"33 1","pages":"2359932"},"PeriodicalIF":1.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141178794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
HyperChildNET COST Action CA19115: report of the task force. 超级儿童网 COST 行动 CA19115:特别工作组报告。
IF 1.8 4区 医学 Pub Date : 2024-12-01 Epub Date: 2024-11-01 DOI: 10.1080/08037051.2024.2421214
E Lurbe, G Mancia, D Drozdz, S Erdine, F Fernandez-Aranda, M Litwin, M D Sinha, G Simonetti, S Stabouli, E Wühl

Purpose: Despite dramatic medical advances over the last few decades, cardiovascular disease remains a leading cause of death globally. High BP is clearly established, but modifiable, risk factor for early disability and death. Although most of the adverse outcomes occur in adulthood it has become clear that high BP is a life course problem that can become evident in early life however, relatively little attention has been paid to the problem of high BP in children and adolescents. Materials and methods: Being aware of the problem and the needs, the Task Force of the ESH Guidelines in children and adolescents took the initiative to move forward in the field, identifying the COST Action program. A proposal, HyperChildNET, was submitted, approved and funded for 4 years starting in October 2020. Results: The aim of the Action has been to establish a European sustainable and multidisciplinary network of researchers, clinicians, early career investigators, health economists, decision-makers, regulatory bodies, and medical devices manufacturers under the umbrella of the European Commission in order to acquire a holistic understanding of those factors affecting high BP in children and adolescents in order to propose and implement preventive and corrective actions. All the activities carried out during the 4 years are described. Conclusions: HyperChildNET offers a European perspective of the issue giving us the opportunity to develop new strategies and objectives moving forward in the field.

目的:尽管过去几十年来医学取得了突飞猛进的发展,但心血管疾病仍然是全球死亡的主要原因。高血压显然是导致早期残疾和死亡的既定但可改变的风险因素。虽然大多数不良后果都发生在成年期,但高血压是一个生命过程问题,在生命早期就会显现,这一点已经很清楚,不过,人们对儿童和青少年高血压问题的关注相对较少。材料和方法:意识到这一问题和需求后,ESH 儿童和青少年指南特别工作组主动在这一领域采取行动,确定了 COST 行动计划。一项名为 "超级儿童网络"(HyperChildNET)的提案已提交,并获得批准和资助,自 2020 年 10 月起为期 4 年。成果:该行动的目的是在欧盟委员会的保护下,建立一个由研究人员、临床医生、早期职业调查人员、卫生经济学家、决策者、监管机构和医疗设备制造商组成的欧洲可持续多学科网络,以全面了解影响儿童和青少年高血压的因素,从而提出并实施预防和纠正措施。本文介绍了 4 年间开展的所有活动。结论:HyperChildNET 从欧洲的角度看待这一问题,为我们在这一领域制定新的战略和目标提供了机会。
{"title":"HyperChildNET COST Action CA19115: report of the task force.","authors":"E Lurbe, G Mancia, D Drozdz, S Erdine, F Fernandez-Aranda, M Litwin, M D Sinha, G Simonetti, S Stabouli, E Wühl","doi":"10.1080/08037051.2024.2421214","DOIUrl":"https://doi.org/10.1080/08037051.2024.2421214","url":null,"abstract":"<p><p><b>Purpose:</b> Despite dramatic medical advances over the last few decades, cardiovascular disease remains a leading cause of death globally. High BP is clearly established, but modifiable, risk factor for early disability and death. Although most of the adverse outcomes occur in adulthood it has become clear that high BP is a life course problem that can become evident in early life however, relatively little attention has been paid to the problem of high BP in children and adolescents. <b>Materials and methods:</b> Being aware of the problem and the needs, the Task Force of the ESH Guidelines in children and adolescents took the initiative to move forward in the field, identifying the COST Action program. A proposal, HyperChildNET, was submitted, approved and funded for 4 years starting in October 2020. <b>Results:</b> The aim of the Action has been to establish a European sustainable and multidisciplinary network of researchers, clinicians, early career investigators, health economists, decision-makers, regulatory bodies, and medical devices manufacturers under the umbrella of the European Commission in order to acquire a holistic understanding of those factors affecting high BP in children and adolescents in order to propose and implement preventive and corrective actions. All the activities carried out during the 4 years are described. <b>Conclusions:</b> HyperChildNET offers a European perspective of the issue giving us the opportunity to develop new strategies and objectives moving forward in the field.</p>","PeriodicalId":9000,"journal":{"name":"Blood Pressure","volume":"33 1","pages":"2421214"},"PeriodicalIF":1.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142557100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
In remembrance: the life and legacy of George L. Bakris (1952-2024). 纪念:乔治-L-巴克里斯(1952-2024 年)的生平与遗产。
IF 1.8 4区 医学 Pub Date : 2024-12-01 Epub Date: 2024-08-19 DOI: 10.1080/08037051.2024.2390774
Pantelis Sarafidis, Kostas Tsioufis, Michel Burnier, Bryan Williams, Giuseppe Mancia, Thomas Weber, George S Stergiou

George L. Bakris passed away on 15 June 2024 at the age of 72 years. This obituary aims at honouring his life and career by describing the stages in his personal and professional pathway, presenting some of his many remarkable accomplishments, and highlighting his exceptional clinical skills, mentorship, and friendship.

乔治-L-巴克里斯于 2024 年 6 月 15 日去世,享年 72 岁。这篇讣告旨在通过描述他个人和职业道路上的各个阶段,介绍他的许多杰出成就,并强调他卓越的临床技能、良师益友和友谊,向他的一生和事业致敬。
{"title":"In remembrance: the life and legacy of George L. Bakris (1952-2024).","authors":"Pantelis Sarafidis, Kostas Tsioufis, Michel Burnier, Bryan Williams, Giuseppe Mancia, Thomas Weber, George S Stergiou","doi":"10.1080/08037051.2024.2390774","DOIUrl":"https://doi.org/10.1080/08037051.2024.2390774","url":null,"abstract":"<p><p>George L. Bakris passed away on 15 June 2024 at the age of 72 years. This obituary aims at honouring his life and career by describing the stages in his personal and professional pathway, presenting some of his many remarkable accomplishments, and highlighting his exceptional clinical skills, mentorship, and friendship.</p>","PeriodicalId":9000,"journal":{"name":"Blood Pressure","volume":"33 1","pages":"2390774"},"PeriodicalIF":1.8,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142003518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Blood Pressure
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1